Clinical trials

3

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Menopausal HT for Women Living With HIV (HoT)

Women living with HIV have been shown to experience more frequent and severe hot flashes and night sweats (collectively known as vasomotor symptoms) as compared to women living without HIV. This correlates with disturbed sleep, increased depressive symptoms, increased anxiety, worse mental function, interference with activities of daily living including work, and worse overall quality of life. Hormone therapy is considered to be the most effective therapy for hot flashes and night sweats and the most appropriate choice to prevent bone loss at the time of menopause for women without HIV. However, the usefulness of hormone therapy has not been specifically studied in women living with HIV. This trial is being done to see if: * There is evidence to support the use of hormone therapy (estradiol with or without progesterone) for the treatment of hot flashes and night sweats in women living with HIV * Hormone therapy improves mental function, mood, sleep, quality of life, bone health, heart health, and inflammation in women living with HIV * Hormone therapy is safe and tolerable for women living with HIV

Participants needed: 105
Trial details
Phase: Phase 4Age: 40-60Biological sex: FemaleType: InterventionalSponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other InfectionsUpdated: May 22, 2026Locations: 23
Eligibility criteria

Living with HIV [+11]

Status: Not yet recruiting

Therapeutic ID93 + GLA-SE Vaccination in Participants With Rifampicin-Susceptible Pulmonary TB

This study is being done to test an experimental study vaccine compared to a placebo. The experimental study vaccine is called ID93 + GLA-SE. ID93 + GLA-SE has been used in humans in research but has not been approved for use in medical care. This study will be the first to test ID93 + GLA-SE in people living with HIV (PLWH). The injections during the study will be given to different groups of participants while they are using standard TB treatment. One of the research questions is to understand the differences in immune system responses depending on the timing of giving the injections after people begin taking standard TB treatment. Researchers also want to continue to look at whether the study vaccine is safe when tested in a larger group of people, and if getting the study vaccine in addition to standard TB treatment can help to lower the number of poor TB outcomes that people might have.

Participants needed: 1,500
Trial details
Phase: Phase 2Age: 18-65Biological sex: AllType: InterventionalSponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other InfectionsUpdated: Apr 9, 2026
Eligibility criteria

Bacteriologically confirmed rifampicin-susceptible pulmonary TB using phenotypic... [+18]

Documented M.tb resistance to isoniazid. [+30]

Status: Recruiting

Observational PIC Destination Cohort

This study is being done to see if people who control HIV without antiretroviral therapy (ART) after receiving an intervention can remain off ART safely. The information collected in this study is also being used to try to understand how people control HIV without ART after receiving an intervention.

Participants needed: 30
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other InfectionsUpdated: Dec 13, 2024Locations: 4
Eligibility criteria

Currently or previously enrolled in a qualifying ACTG or non- ACTG parent study... [+18]

Intercurrent illness, new medical diagnosis, laboratory abnormality, sign, or sy... [+2]